Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.

scientific article published on 4 August 2017

Empagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1016/J.JACBTS.2017.07.003
P932PMC publication ID6034464
P698PubMed publication ID30062155

P2093author name stringSubodh Verma
Jason R B Dyck
Paul W M Fedak
Donna L Beker
Grant Masson
Nikole J Byrne
Nirmal Parajuli
Jamie Boisvenue
Jody L Levasseur
P2860cites workSGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms?Q26750510
Effects of Six Kinds of Sodium-Glucose Cotransporter 2 Inhibitors on Metabolic Parameters, and Summarized Effect and Its Correlations With Baseline DataQ33763316
Longitudinal arrhythmogenic remodelling in a mouse model of longstanding pressure overloadQ34195594
Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1)Q34264473
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 DiabetesQ34673134
Myocardial ATGL overexpression decreases the reliance on fatty acid oxidation and protects against pressure overload-induced cardiac dysfunctionQ35739201
Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitusQ36622125
Normalization of cardiac substrate utilization and left ventricular hypertrophy precede functional recovery in heart failure regression.Q36812665
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patientsQ37524302
Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetesQ37586729
Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heartQ37794503
Biology of human sodium glucose transportersQ37870037
Fibrosis and heart failureQ38057701
Lower Risk of Heart Failure and Death in Patients Initiated on Sodium-Glucose Cotransporter-2 Inhibitors Versus Other Glucose-Lowering Drugs: The CVD-REAL Study (Comparative Effectiveness of Cardiovascular Outcomes in New Users of Sodium-Glucose CotQ38376619
Effect of empagliflozin on cardiac biomarkers in a zebrafish model of heart failure: clues to the EMPA-REG OUTCOME trial?Q38845967
Resveratrol improves exercise performance and skeletal muscle oxidative capacity in heart failure.Q38979963
Resveratrol treatment of mice with pressure-overload-induced heart failure improves diastolic function and cardiac energy metabolismQ42703629
Glucose-transporter-mediated positive inotropic effects in human myocardium of diabetic and nondiabetic patientsQ43203524
QRS duration and mortality in patients with congestive heart failureQ44035548
Canagliflozin and Cardiovascular and Renal Events in Type 2 DiabetesQ47373645
Effect of Empagliflozin on Left Ventricular Mass and Diastolic Function in Individuals With Diabetes: An Important Clue to the EMPA-REG OUTCOME Trial?Q47384272
Inhibition of Renal Sodium-Glucose Cotransport With Empagliflozin Lowers Fasting Plasma Glucose and Improves β-Cell Function in Subjects With Impaired Fasting Glucose.Q48283389
Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits.Q51382208
CV Protection in the EMPA-REG OUTCOME Trial: A "Thrifty Substrate" Hypothesis.Q51707689
Empagliflozin's Fuel Hypothesis: Not so Soon.Q52855314
Heterogeneous Connexin43 distribution in heart failure is associated with dispersed conduction and enhanced susceptibility to ventricular arrhythmiasQ54952185
Relation of dispersion of QRS and QT in patients with advanced congestive heart failure to cardiac and sudden death mortalityQ73763738
P433issue4
P921main subjectempagliflozinQ5373824
P304page(s)347-354
P577publication date2017-08-04
P1433published inJACC. Basic to Translational ScienceQ27727237
P1476titleEmpagliflozin Prevents Worsening of Cardiac Function in an Experimental Model of Pressure Overload-Induced Heart Failure.
P478volume2

Reverse relations

cites work (P2860)
Q89617548Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors
Q58725666Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection
Q89920670Comparative Study of the Effects of GLP1 Analog and SGLT2 Inhibitor against Diabetic Cardiomyopathy in Type 2 Diabetic Rats: Possible Underlying Mechanisms
Q59813541Direct Cardiac Actions of Sodium Glucose Cotransporter 2 Inhibitors Target Pathogenic Mechanisms Underlying Heart Failure in Diabetic Patients
Q98566233Does empagliflozin modulate the autonomic nervous system among individuals with type 2 diabetes and coronary artery disease? The EMPA-HEART CardioLink-6 Holter analysis
Q64105820Empagliflozin Improves Diastolic Function in a Nondiabetic Rodent Model of Heart Failure With Preserved Ejection Fraction
Q93229030Empagliflozin Increases Cardiac Energy Production in Diabetes: Novel Translational Insights Into the Heart Failure Benefits of SGLT2 Inhibitors
Q93058591Empagliflozin and HFrEF: Known and Possible Benefits of NHE1 Inhibition
Q98386175Empagliflozin improves post-infarction cardiac remodeling through GTP enzyme cyclohydrolase 1 and irrespective of diabetes status
Q58802559Empagliflozin reduces Ca/calmodulin-dependent kinase II activity in isolated ventricular cardiomyocytes
Q90478430Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial
Q90026288Inhibition of sodium-glucose cotransporter-2 preserves cardiac function during regional myocardial ischemia independent of alterations in myocardial substrate utilization
Q96955195Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors: A State-of-the-Art Review
Q64982195Refueling the Failing Heart: A Case for Sodium-Glucose Cotransporter 2 Inhibition in Cardiac Energy Homeostasis.
Q90676214SGLT-2 Inhibitors in Heart Failure: Current Management, Unmet Needs, and Therapeutic Prospects
Q92863133SGLT2 Inhibitors Play a Salutary Role in Heart Failure via Modulation of the Mitochondrial Function
Q61801176SGLT2 inhibition with empagliflozin attenuates myocardial oxidative stress and fibrosis in diabetic mice heart
Q61797815SGLT2 inhibition with empagliflozin improves coronary microvascular function and cardiac contractility in prediabetic ob/ob mice
Q63071416SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review
Q91593292Sodium-glucose co-transporter 2 inhibition with empagliflozin improves cardiac function in non-diabetic rats with left ventricular dysfunction after myocardial infarction
Q89465086Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease
Q64105830The Growing Case for Use of SGLT2i in Heart Failure: Additional Benefits of Empagliflozin in a HFpEF Rodent Model
Q92916727The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit
Q92537722The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions
Q60928393Update on heart failure management and future directions